Novo Nordisk (NOVOB.DK) shares are losing 20% after the pharmaceutical giant, known for its obesity drugs Ozempic and Wegova, released disappointing clinical trial data for its experimental obesity drug CagriSema. Patients treated with Novo's next-generation weight-loss drug CagriSema lost an average of 22.7% of their weight after 68 weeks, falling short of the 25% goal the drugmaker expected. About 40% of patients lost 25% or more of their body weight.

The company's shares are trading at their lowest since August 2023. Source: xStation
Daily summary: Banks and tech drag indices up 🏭US industry stays strong
Largest in its class: What do BlackRock’s earnings say about the market?
US OPEN: Bank and fund earnings support valuations.
MIDDAY WRAP: Capital flows into European technology stocks 💸🔎